For the quarter ending 2025-10-31, KEQU had -$6,762K decrease in cash & cash equivalents over the period. -$5,835K in free cash flow.
| Cash Flow | 2025-10-31 | 2025-07-31 |
|---|---|---|
| Net earnings | 2,538 | 3,159 |
| Depreciation and amortization | 1,580 | 1,549 |
| Provision for credit losses | -50 | 19 |
| Stock-based compensation expense | 561 | 521 |
| Deferred income taxes | 437 | -154 |
| Accrued payment in kind ('pik') interest | 490 | 445 |
| Amortization of deferred financing costs | 94 | 94 |
| Receivables | 2,070 | -5,468 |
| Inventories | 576 | 2,074 |
| Income tax receivable | 246 | - |
| Accounts payable and other accrued expenses | -4,908 | -1,525 |
| Deferred revenue | -642 | -1,090 |
| Other, net | 397 | -621 |
| Net cash provided by operating activities | -4,265 | 5,791 |
| Capital expenditures | 1,570 | 771 |
| Net cash used in investing activities | -1,570 | -771 |
| Dividends paid to non-controlling interest in subsidiaries | 0 | - |
| Repayments on term loan | 750 | 750 |
| Proceeds from short-term borrowings | 1,979 | 1,377 |
| Repayments on short-term borrowings | 1,356 | 1,869 |
| Payments on sale-leaseback financing transaction | 209 | 207 |
| Proceeds from long-term lease obligations | 226 | - |
| Payments on long-term lease obligations | 72 | 14 |
| Employee taxes withheld for stock-based compensation in stock | 671 | - |
| Net cash used in financing activities | -853 | -1,463 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -74 | -280 |
| (decrease) increase in cash, cash equivalents and restricted cash | -6,762 | 3,277 |
| Cash and cash equivalents at beginning of period | 17,164 | - |
| Cash and cash equivalents at end of period | 13,679 | - |
KEWAUNEE SCIENTIFIC CORP DE (KEQU)
KEWAUNEE SCIENTIFIC CORP DE (KEQU)